{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:03:46Z","timestamp":1787317426600,"version":"build-2736575974"},"reference-count":118,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRCEP"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Helicobacter pylori infects at least 50% of the world\u2019s human population. The\ncurrent study aimed to assess and compare the efficacy of triple versus quadruple therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Randomized clinical trials (RCTs) consisting of triple and quadruple therapy were identified\nthrough electronic and manual searches in the national and international online databases (IsI, Magiran,\nEmbase, PubMed, and Scopus). The random-effects model was applied to pool analysis. Funnel\nplots and the Egger test were used to examine publication bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>After a detailed review of the selected articles, 80 RCTs were included in the meta-analysis;\nit was based on using triple and quadruple therapy as the first and second-line treatment. The results\nshowed that quadruple therapy in the first-line treatment had a higher eradication rate than triple therapy.\nOverall, the eradication rate with triple therapy was 74% (95% CI, 71%-77%) for intention-totreat\n(ITT) analysis and 80% (95% CI, 77%-82%) for per-protocol (PP) analysis. Generally, the eradication\nrate with quadruple therapy was 82% (95% CI, 78.0%-86.0%) for ITT analysis and 85% (95%\nCI, 82.0%-89.0%) for PP analysis. The analysis also revealed that quadruple therapy was more effective\nfor 7 or 10 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The current study results demonstrated that quadruple therapy has better effectiveness\nthan triple therapy as the first-line treatment; however, in the second-line treatment, the effectiveness\nof quadruple and triple regimens is almost similar. The effectiveness of quadruple therapy in the Asian\npopulation was found to be slightly higher than that of triple therapy, while this difference was considerably\nhigher in the European population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/2772432818666230120111237","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T01:28:12Z","timestamp":1674437292000},"page":"184-203","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Novel Information Regarding the Treatment of Helicobacter pylori Infection:\nA Systematic Review and Meta-analysis of Randomized Clinical Trials"],"prefix":"10.2174","volume":"19","author":[{"given":"Faezeh","family":"Kiani","sequence":"first","affiliation":[{"name":"Student Research Committee, Ilam University of Medical Sciences, Ilam, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Khademolhosseini","sequence":"additional","affiliation":[{"name":"School of Medicine, Shiraz University\nof Medical Sciences, Fars, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasem","family":"Mohammadi","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam,\nIran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arian","family":"Tavasol","sequence":"additional","affiliation":[{"name":"Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran,\nIran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramtin","family":"Hajibeygi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran,\nIran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobina","family":"Fathi","sequence":"additional","affiliation":[{"name":"Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran,\nIran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Dousti","sequence":"additional","affiliation":[{"name":"Department of Parasitology, Faculty of Medicine, Shiraz University of Medical Sciences, Fars, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1523-5378.2011.00826.x","volume":"16","author":"Wu C.","year":"2011","unstructured":"Wu C.; Chen X.; Liu J.; Li M.Y.; Zhang Z.Q.; Wang Z.Q.; Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: A meta-analysis. Helicobacter 2011,16(2),131-138","journal-title":"Helicobacter"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMcp1001110","volume":"362","author":"McColl K.E.L.","year":"2010","unstructured":"McColl K.E.L.; Helicobacter pylori Infection. N Engl J Med 2010,362(17),1597-1604","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3748\/wjg.v19.i6.931","volume":"19","author":"Ma H.J.","year":"2013","unstructured":"Ma H.J.; Wang J.L.; Quadruple therapy for eradication of Helicobacter pylori. World J Gastroenterol 2013,19(6),931-935","journal-title":"World J Gastroenterol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4251\/wjgo.v4.i7.156","volume":"4","author":"Nagini S.","year":"2012","unstructured":"Nagini S.; Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 2012,4(7),156-169","journal-title":"World J Gastrointest Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000350719","volume":"88","author":"Venerito M.","year":"2013","unstructured":"Venerito M.; Krieger T.; Ecker T.; Leandro G.; Malfertheiner P.; Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013,88(1),33-45","journal-title":"Digestion"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/hel.12034","volume":"18","author":"Lim J.H.","year":"2013","unstructured":"Lim J.H.; Lee D.H.; Choi C.; Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori erad- ication: A randomized pilot study. Helicobacter 2013,18,180-186","journal-title":"Helicobacter"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"5669","DOI":"10.3748\/wjg.v18.i40.5669","volume":"18","author":"Caro S.D.","year":"2012","unstructured":"Caro S.D.; Fini L.; Daoud Y.; Levofloxacin\/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol 2012,18(40),5669-5678","journal-title":"World J Gastroenterol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1136\/gut.2003.022111","volume":"53","author":"M\u00e9graud F.","year":"2004","unstructured":"M\u00e9graud F.; H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004,53(9),1374-1384","journal-title":"Gut"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1523-5378.2008.00639.x","volume":"13","author":"Egan B.J.","year":"2008","unstructured":"Egan B.J.; Marzio L.; O\u2019Connor H.; O\u2019Morain C.; Treatment of Helicobacter pylori infection. Helicobacter 2008,13(1),35-40","journal-title":"Helicobacter"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/09674845.2010.11730319","volume":"67","author":"Yakoob J.","year":"2010","unstructured":"Yakoob J.; Abid S.; Abbas Z.; Jafri S.N.W.; Antibiotic susceptibility patterns of Helicobacter pylori and triple therapy in a high-prevalence area. Br J Biomed Sci 2010,67(4),197-201","journal-title":"Br J Biomed Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","volume":"62","author":"Megraud F.","year":"2013","unstructured":"Megraud F.; Coenen S.; Versporten A.; Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic con-sumption. Gut 2013,62(1),34-42","journal-title":"Gut"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1136\/gut.2007.132514","volume":"56","author":"Megraud F.","year":"2007","unstructured":"Megraud F.; Helicobacter pylori and antibiotic resistance. Gut 2007,56(11),1502","journal-title":"Gut"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/MAJ.0b013e3181b5d3cf","volume":"338","author":"Demir M.","year":"2009","unstructured":"Demir M.; Gokturk H.S.; Ozturk N.A.; Serin E.; Yilmaz U.; Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: A randomized con-trolled study. Am J Med Sci 2009,338(6),459-464","journal-title":"Am J Med Sci"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1046\/j.1365-2036.2003.01566.x","volume":"17","author":"Gen\u00e9 E.","year":"2003","unstructured":"Gen\u00e9 E.; Calvet X.; Azagra R.; Triple vs. quadruple therapy for treating Helicobacter pylori infection: A meta-analysis. Aliment Pharmacol Ther 2003,17(9),1137-1143","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1572-0241.2003.t01-1-07288.x","volume":"98","author":"Laine L.","year":"2003","unstructured":"Laine L.; Hunt R.; El-Zimaity H.; Nguyen B.; Osato M.; Sp\u00e9nard J.; Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: A prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003,98(3),562-567","journal-title":"Am J Gastroenterol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1046\/j.1365-2036.2002.01278.x","volume":"16","author":"Calvet X.","year":"2002","unstructured":"Calvet X.; Ducons J.; Guardiola J.; One-week triple vs. quadruple therapy for Helicobacter pylori infection - A randomized trial. Aliment Pharmacol Ther 2002,16(7),1261-1267","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ajg.2013.03.002","volume":"14","author":"Vafaeimanesh J.","year":"2013","unstructured":"Vafaeimanesh J.; Rajabzadeh R.; Ahmadi A.; Moshtaghi M.; Banikarim S.; Effect of Helicobacter pylori eradication on glycaemia control in patients with type 2 diabetes mellitus and comparison of two therapeutic regimens. Arab J Gastroenterol 2013,14,55-58","journal-title":"Arab J Gastroenterol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1517\/14656566.2013.782286","volume":"14","author":"Marin A.C.","year":"2013","unstructured":"Marin A.C.; McNicholl A.G.; Gisbert J.P.; A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobac-ter pylori eradication). Expert Opin Pharmacother 2013,14(7),843-861","journal-title":"Expert Opin Pharmacother"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","volume":"61","author":"Malfertheiner P.","year":"2012","unstructured":"Malfertheiner P.; Megraud F.; O\u2019Morain C.A.; Management of Helicobacter pylori infection\u2013 the Maastricht IV\/Florence consen- sus report. Gut 2012,61(5),646-664","journal-title":"Gut"},{"key":"ref=20","first-page":"91","volume":"15","author":"Fattahi E.","year":"2004","unstructured":"Fattahi E.; Azargoon A.; Fakhrju A.; 7 and 14 days compared to triple therapy containing clarithromycin, amoxicillin and omeprazole in the treatment of Helicobacter pylori. Majallah-i Pizishki-i Urumiyyah 2004,15(2),91-85","journal-title":"Majallah-i Pizishki-i Urumiyyah"},{"key":"ref=21","volume":"9","author":"Bahar I.A.","year":"2007","unstructured":"Bahar I.A.; Nezam S.K.; Karimi M.; Firoozeh K.; The comparison of two combination antibiotic [(OAB-T) VS (OAB-F)] regimen tro- phy in peptic ulcer and dyspepsia patients. TabibShargh Journal 2007,9(4)","journal-title":"TabibShargh Journal"},{"key":"ref=22","first-page":"203","volume":"14","author":"Hashemi S.M.","year":"2007","unstructured":"Hashemi S.M.; HaghAzali M, Mirzaii M, Sohrabpour AA. The efficacy of two-week Metronidazole, Amoxicillin-based quadruple therapy for eradication of Helicobacter Pylori Infection in Iranian patients. Iran University of Medical Sciences 2007,14(54),203-208","journal-title":"Iran University of Medical Sciences"},{"key":"ref=23","first-page":"238","volume":"13","author":"Rafii M.","year":"2008","unstructured":"Rafii M.; Qvjazadh M.; Performance comparison of metronidazole and clarithromycin in the eradication of Helicobacter pylori in children. Gastroenterology 2008,13(4),238-3","journal-title":"Gastroenterology"},{"key":"ref=24","first-page":"245","volume":"5","author":"Khalighi A.R.","year":"2009","unstructured":"Khalighi A.R.; Khalighi M.R.; Ghasemi S.M.; Khalighi N.; Comparison of the two-drug regimen consisting of amoxicillin and metronidazole, clarithromycin and omeprazole for eradication of Helicobacter pylori infection in patients with peptic ulcer. Medical Science Journal of Islamic Azad University of Mashhad 2009,5(4),245-251","journal-title":"Medical Science Journal of Islamic Azad University of Mashhad"},{"key":"ref=25","first-page":"443","volume":"8","author":"Hashemi S.J.","year":"2010","unstructured":"Hashemi S.J.; Hajiani E.; Masjedizadeh A.; Shayesteh A.; AbooAli A. Comparison of a triple therapy regimen containing ciprofloxacin and low dose furazolidone with conventional quadruple regimen for Helicobacter Pylori eradication. Sci Med J 2010,8(4),443-454","journal-title":"Sci Med J"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1053\/j.gastro.2005.09.007","volume":"129","author":"Francavilla R.","year":"2005","unstructured":"Francavilla R.; Lionetti E.; Castellaneta S.P.; Improved efficacy of 10 Day sequential treatment for Helicobacter pylori eradication in children: A randomized trial. Gastroenterology 2005,129(5),1414-1419","journal-title":"Gastroenterology"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0016-5085(99)70119-8","volume":"116","author":"Lind T.","year":"1999","unstructured":"Lind T.; M\u00e9graud F.; Unge P.; The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple thera-pies. Gastroenterology 1999,116(2),248-253","journal-title":"Gastroenterology"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1046\/j.1365-2036.1999.00504.x","volume":"13","author":"Lee J.M.","year":"1999","unstructured":"Lee J.M.; Breslin N.P.; Hyde D.K.; Buckley M.J.; O\u2019Morain C.A.; Treatment options for Helicobacter pylori infection when proton pump inhib-itor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999,13(4),489-496","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1046\/j.1365-2036.1999.00615.x","volume":"13","author":"Gisbert J.P.","year":"1999","unstructured":"Gisbert J.P.; Gisbert J.L.; Marcos S.; Gr\u00e1valos R.G.; Carpio D.; Pajares J.M.; Seven-day \u2018rescue\u2019 therapy after Helicobacter pylori treatment failure: Omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999,13(10),1311-1316","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S1542-3565(04)00458-6","volume":"2","author":"Bilardi C.","year":"2004","unstructured":"Bilardi C.; Dulbecco P.; Zentilin P.; A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: A controlled trial. Clin Gastroenterol Hepatol 2004,2(11),997-1002","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S1590-8658(03)00059-8","volume":"35","author":"Zullo A.","year":"2003","unstructured":"Zullo A.; Hassan C.; De Francesco V.; A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis 2003,35(4),232-236","journal-title":"Dig Liver Dis"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.dld.2005.01.017","volume":"37","author":"Zullo A.","year":"2005","unstructured":"Zullo A.; De Francesco V.; Scaccianoce G.; Quadruple therapy with lactoferrin for Helicobacter pylori eradication: A randomised, multicentre study. Dig Liver Dis 2005,37(7),496-500","journal-title":"Dig Liver Dis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.dld.2007.05.021","volume":"39","author":"Zullo A.","year":"2007","unstructured":"Zullo A.; De Francesco V.; Scaccianoce G.; Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: A multicentre study. Dig Liver Dis 2007,39(9),806-810","journal-title":"Dig Liver Dis"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajg.2012.12.004","volume":"14","author":"Seyedmajidi S.","year":"2013","unstructured":"Seyedmajidi S.; Mirsattari D.; Zojaji H.; Penbactam for Helicobacter pylori eradication: A randomised comparison of quadruple and triple treatment schedules in an Iranian population. Arab J Gastroenterol 2013,14(1),1-5","journal-title":"Arab J Gastroenterol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3748\/wjg.v10.i5.747","volume":"10","author":"Guo C.Y.","year":"2004","unstructured":"Guo C.Y.; Wu Y.B.; Liu H.L.; Wu J.Y.; Zhong M.Z.H.; Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection. World J Gastroenterol 2004,10(5),747-749","journal-title":"World J Gastroenterol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1471-230X-7-31","volume":"7","author":"Navarro-Jarabo J.M.","year":"2007","unstructured":"Navarro-Jarabo J.M.; Fern\u00e1ndez N.; Sousa F.L.; Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helico-bacter pylori infection. BMC Gastroenterol 2007,7(1),31","journal-title":"BMC Gastroenterol"},{"key":"ref=37","first-page":"273","volume":"53","author":"Wang Z.","year":"2012","unstructured":"Wang Z.; Wu S.; Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: An open-label control study in Chinese patients. Singapore Med J 2012,53(4),273-276","journal-title":"Singapore Med J"},{"key":"ref=38","author":"Houben M.","year":"2010","unstructured":"Houben M.; Efficacy of proton pump inhibitor-based triple therapy in Helicobacter pylori infected patients with peptic ulcer disease ver-sus functional dyspepsia. The Institutional Repository of the\tUniversity of Amsterdam (UvA) 2010","journal-title":"The Institutional Repository of the\tUniversity of Amsterdam (UvA)"},{"key":"ref=39","first-page":"303","volume":"31","author":"Aminian K.","year":"2010","unstructured":"Aminian K.; Farsad F.; Ghanbari A.; Fakhreih S.; Hasheminasab S.M.; A randomized trial comparing four Helicobacter pylori eradication regimens: Standard triple therapy, ciprofloxacin based triple therapy, quadruple and sequential therapy. Trop Gastroenterol 2010,31(4),303-307","journal-title":"Trop Gastroenterol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1365-2036.1999.00462.x","volume":"13","author":"Rinaldi V","year":"1999","unstructured":"Rinaldi V; Zullo A; Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther 1999,13(2),163-168","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1046\/j.1365-2036.2000.00674.x","volume":"14","author":"Chan F.K.L.","year":"2000","unstructured":"Chan F.K.L.; Sung J.J.Y.; Suen R.; Wu J.C.Y.; Ling T.K.W.; Chung S.C.S.; Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. Aliment Pharmacol Ther 2000,14(1),91-95","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1046\/j.1365-2036.2000.00719.x","volume":"14","author":"Perri F.","year":"2000","unstructured":"Perri F.; Festa V.; Clemente R.; Quitadamo M.; Andriulli A.; Rifabutin-based \u2018rescue therapy\u2019 for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000,14(3),311-316","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1046\/j.1365-2036.2000.00761.x","volume":"14","author":"Michopoulos S.","year":"2000","unstructured":"Michopoulos S.; Tsibouris P.; Bouzakis H.; Randomized study comparing omeprazole with ranitidine as anti-secretory agents com-bined in quadruple second-line Helicobacter pylori eradication regimens. Aliment Pharmacol Ther 2000,14(6),737-744","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1046\/j.1365-2036.2000.00845.x","volume":"14","author":"Liu W.Z.","year":"2000","unstructured":"Liu W.Z.; Xiao S.D.; Hu P.J.; Lu H.; Cui Y.; Tytgat G.N.J.; A new quadruple therapy for Helicobacter pylori using tripotassium dicitrato bis-muthate, furazolidone, josamycin and famotidine. Aliment Pharmacol Ther 2000,14(11),1519-1522","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1046\/j.1365-2036.2002.01220.x","volume":"16","author":"Georgopoulos S.D.","year":"2002","unstructured":"Georgopoulos S.D.; Ladas S.D.; Karatapanis S.; Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Aliment Pharmacol Ther 2002,16(3),569-575","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1046\/j.1365-2036.2002.01299.x","volume":"16","author":"Isakov V.","year":"2002","unstructured":"Isakov V.; Domareva I.; Koudryavtseva L.; Maev I.; Ganskaya Z.; Furazolidone-based triple \u2018rescue therapy\u2019 vs. quadruple \u2018rescue thera-py\u2019 for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther 2002,16(7),1277-1282","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1046\/j.1365-2036.2002.01304.x","volume":"16","author":"Boixeda D.","year":"2002","unstructured":"Boixeda D.; Bermejo F.; Mart\u00edn-De-Argila C.; Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronida-zole as rescue treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2002,16(8),1457-1460","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1046\/j.1365-2036.2003.01434.x","volume":"17","author":"O\u2019Morain C.","year":"2003","unstructured":"O\u2019Morain C.; Borody T.; Farley A.; Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracy-cline, given with omeprazole, for the eradication of Helicobacter pylori: An international multicentre study. Aliment Pharmacol Ther 2003,17(3),415-420","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1046\/j.1365-2036.2003.01459.x","volume":"17","author":"Wong W.M.","year":"2003","unstructured":"Wong W.M.; Gu Q.; Lam S.K.; Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003,17(4),553-560","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1046\/j.1365-2036.2003.01653.x","volume":"18","author":"Chi C.H.","year":"2003","unstructured":"Chi C.H.; Lin C.Y.; Sheu B.S.; Yang H.B.; Huang A.H.; Wu J.J.; Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment Pharmacol Ther 2003,18(3),347-353","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/j.1365-2036.2005.02465.x","volume":"21","author":"Gisbert J.P.","year":"2005","unstructured":"Gisbert J.P.; Fuentes J.; Carpio D.; 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2005,21(10),1249-1253","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1365-2036.2010.04274.x","volume":"31","author":"Molina-Infante J.","year":"2010","unstructured":"Molina-Infante J.; Perez-Gallardo B.; Fernandez-Bermejo M.; Clinical trial: clarithromycin vs. levofloxacin in first-line triple and se-quential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010,31(10),1077-1084","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1523-5378.2007.00588.x","volume":"13","author":"Miehlke S.","year":"2008","unstructured":"Miehlke S.; Schneider Brachert W.; One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2008,13,69-74","journal-title":"Helicobacter"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3346\/jkms.2011.26.6.785","volume":"26","author":"Choi K.H.","year":"2011","unstructured":"Choi K.H.; Chung W.C.; Lee K.M.; Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: A double-blind, randomized controlled trial. J Korean Med Sci 2011,26(6),785-790","journal-title":"J Korean Med Sci"},{"key":"ref=55","first-page":"30","volume":"47","author":"Kang M.S.","year":"2006","unstructured":"Kang M.S.; Park D.I.I.; Yun J.W.; Levofloxacin-azithromycin combined triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2006,47(1),30-36","journal-title":"Korean J Gastroenterol"},{"key":"ref=56","first-page":"285","volume":"51","author":"Jung H.S.","year":"2008","unstructured":"Jung H.S.; Shim K.N.; Baik S.J.; Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication. Korean J Gastroenterol 2008,51(5),285-290","journal-title":"Korean J Gastroenterol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJM199812243392602","volume":"339","author":"Blum A.L.","year":"1998","unstructured":"Blum A.L.; Talley N.J.; O\u2019Mor\u00e1in C.; Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 1998,339(26),1875-1881","journal-title":"N Engl J Med"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/gut.42.2.166","volume":"42","author":"van der Hulst R.W.M.","year":"1998","unstructured":"van der Hulst R.W.M.; van der Ende A.; Homan A.; Roorda P.; Dankert J.; Tytgat G.N.J.; Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication. Gut 1998,42(2),166-169","journal-title":"Gut"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.3748\/wjg.v16.i34.4357","volume":"16","author":"Gao X.Z.","year":"2010","unstructured":"Gao X.Z.; Qiao X.L.; Song W.; Wang W.F.; Liu F.; Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. World J Gastroenterol 2010,16(34),4357-4362","journal-title":"World J Gastroenterol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/hel.12062","volume":"18","author":"Georgopoulos S.D.","year":"2013","unstructured":"Georgopoulos S.D.; Xirouchakis E.; Martinez-Gonzalez B.; Clinical evaluation of a ten-day regimen with esomeprazole, metronida-zole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. Helicobacter 2013,18(6),459-467","journal-title":"Helicobacter"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/hel.12056","volume":"18","author":"Calhan T.","year":"2013","unstructured":"Calhan T.; Kahraman R.; Sahin A.; Efficacy of two levofloxacin containing second-line therapies for Helicobacter pylori: A pilot study. Helicobacter 2013,18,378-383","journal-title":"Helicobacter"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/hel.12052","volume":"18","author":"Liao J.","year":"2013","unstructured":"Liao J.; Zheng Q.; Liang X.; Effect of fluoroquinolone resistance on 14-day levofloxacin triple and tripleplus bismuth quadruple therapy. Helicobacter 2013,18,373-377","journal-title":"Helicobacter"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/jac\/dks361","volume":"68","author":"Kuo C.H.","year":"2013","unstructured":"Kuo C.H.; Hsu P.I.; Kuo F.C.; Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: A randomized controlled trial. J Antimicrob Chemother 2013,68(1),222-228","journal-title":"J Antimicrob Chemother"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/apt.12089","volume":"36","author":"Tay C.Y.","year":"2012","unstructured":"Tay C.Y.; Windsor H.M.; Thirriot F.; Helicobacter pylori eradication in Western Australia using novel quadruple therapy combina-tions. Aliment Pharmacol Ther 2012,36(11-12),1076-1083","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1523-5378.2012.00971.x","volume":"17","author":"Liang J.","year":"2012","unstructured":"Liang J.; Li J.; Han Y.; Helicobacter pylori eradication with ecabet sodium, omeprazole, amoxicillin, and clarithromycin versus bis-muth, omeprazole, amoxicillin, and clarithromycin quadruple therapy: A randomized, open-label, phase IV trial. Helicobacter 2012,17(6),458-465","journal-title":"Helicobacter"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/apt.12808","volume":"40","author":"Delchier J.C.","year":"2014","unstructured":"Delchier J.C.; Malfertheiner P.; Thieroff-Ekerdt R.; Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 2014,40(2),171-177","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1523-5378.2012.00947.x","volume":"17","author":"Molina-Infante J.","year":"2012","unstructured":"Molina-Infante J.; Pazos-Pacheco C.; Vinagre-Rodriguez G.; Nonbismuth quadruple (concomitant) therapy: Empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromy-cin-resistant strains. Helicobacter 2012,17(4),269-276","journal-title":"Helicobacter"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1523-5378.2012.00945.x","volume":"17","author":"Manfredi M.","year":"2012","unstructured":"Manfredi M.; Bizzarri B.; Helicobacter pylori infection: Sequential therapy followed by Levofloxacin-containing triple therapy provides a good cumulative eradication rate. Helicobacter 2012,17(4),246-253","journal-title":"Helicobacter"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1523-5378.2011.00896.x","volume":"17","author":"Fakheri H.","year":"2012","unstructured":"Fakheri H.; Taghvaei T.; Hosseini V.; Bari Z.; A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: A randomized clinical trial. Helicobacter 2012,17(1),43-48","journal-title":"Helicobacter"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1523-5378.2007.00472.x","volume":"12","author":"Gisbert J.P.","year":"2007","unstructured":"Gisbert J.P.; Gisbert J.L.; Marcos S.; Moreno-Otero R.; Pajares J.M.; Levofloxacin vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure. Helicobacter 2007,12(1),68-73","journal-title":"Helicobacter"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.0083-8703.2006.00371.x","volume":"11","author":"Cheon J.H.","year":"2006","unstructured":"Cheon J.H.; Kim N.; Lee D.H.; Efficacy of Moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 2006,11,46-51","journal-title":"Helicobacter"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1523-5378.2005.00288.x","volume":"10","author":"Marko D.","year":"2005","unstructured":"Marko D.; Calvet X.; Ducons J.; Guardiola J.; Tito L.; Bory F and the GRESCA (Group for eradication studies from catalonia and arag\u00f3n). Comparison of two management strategies for Helicobacter pylori treatment: Clinical study and cost-effectiveness analysis. Helicobacter 2005,10,22-32","journal-title":"Helicobacter"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1046\/j.1440-1746.2001.02416.x","volume":"16","author":"Sotudehmanesh R.","year":"2001","unstructured":"Sotudehmanesh R.; Malekzadeh R.; Fazeli A.; Massarrat S.; Ziad Alizadeh B.; Eshraghian M.R.; A randomize controlled compari- son of three quadruple therapy regimens in a population with low Helicobacter pylori eradication rates. J Gastroenterol Hepatol 2001,16,264-268","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1523-5378.2006.00459.x","volume":"11","author":"Paoluzi P.","year":"2006","unstructured":"Paoluzi P.; Iacopini F.; Crispino P.; 2-Week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: A large prospective single-center randomized study. Helicobacter 2006,11,562-568","journal-title":"Helicobacter"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s10620-006-9522-5","volume":"52","author":"Subei I.M.","year":"2007","unstructured":"Subei I.M.; Cardona H.J.; Bachelet E.; One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients. Dig Dis Sci 2007,52(6),1505-1512","journal-title":"Dig Dis Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1523-5378.2011.00848.x","volume":"16","author":"Gu L.Y.","year":"2011","unstructured":"Gu L.Y.; Lin W.W.; Lu H.; Chen X.Y.; Ge Z.Z.; Li X.B.; Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: A randomized pilot study. Helicobacter 2011,16(4),284-288","journal-title":"Helicobacter"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1523-5378.2010.00761.x","volume":"15","author":"Kuo C.H.","year":"2010","unstructured":"Kuo C.H.; Wang S.S.W.; Hsu W.H.; Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter 2010,15(4),265-272","journal-title":"Helicobacter"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1523-5378.2010.00758.x","volume":"15","author":"Sun Q.","year":"2010","unstructured":"Sun Q.; Liang X.; Zheng Q.; High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helico-bacter pylori eradication. Helicobacter 2010,15(3),233-238","journal-title":"Helicobacter"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1007\/s10620-008-0547-9","volume":"54","author":"Dehghani S.M.","year":"2009","unstructured":"Dehghani S.M.; Erjaee A.; Imanieh M.H.; Haghighat M.; Efficacy of the standard quadruple therapy versus triple therapies containing proton pump inhibitor plus amoxicillin and clarithromycin or amoxicillin-clavulanic acid and metronidazole for Helicobacter pylori eradication in children. Dig Dis Sci 2009,54(8),1720-1724","journal-title":"Dig Dis Sci"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1001\/archinte.163.17.2079","volume":"163","author":"Lara L.F.","year":"2003","unstructured":"Lara L.F.; Cisneros G.; Gurney M.; One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection. Arch Intern Med 2003,163(17),2079-2084","journal-title":"Arch Intern Med"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1751-2980.2007.00308.x","volume":"8","author":"Uygun A.","year":"2007","unstructured":"Uygun A.; Kadayifci A.; Safali M.; Ilgan S.; Bagci S.; The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori. J Dig Dis 2007,8(4),211-215","journal-title":"J Dig Dis"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1440-1746.2007.04984.x","volume":"23","author":"Uygun A.","year":"2008","unstructured":"Uygun A.; Ozel A.M.; Yildiz O.; Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turk-ish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy. J Gastroenterol Hepatol 2008,23(1),42-45","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1046\/j.1365-2036.2001.00929.x","volume":"15","author":"Nagahara A.","year":"2001","unstructured":"Nagahara A.; Miwa H.; Yamada T.; Kurosawa A.; Ohkura R.; Sato N.; Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2001,15(3),417-421","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1046\/j.1523-5378.2000.00013.x","volume":"5","author":"Nagahara A.","year":"2000","unstructured":"Nagahara A.; Miwa H.; Ogawa K.; Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 2000,5(2),88-93","journal-title":"Helicobacter"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1751-2980.2010.00457.x","volume":"11","author":"Zheng Q.","year":"2010","unstructured":"Zheng Q.; Chen W.J.; Lu H.; Sun Q.J.; Xiao S.D.; Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helico-bacter pylori and antibiotic resistance. J Dig Dis 2010,11(5),313-318","journal-title":"J Dig Dis"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.0083-8703.2006.00375.x","volume":"11","author":"Antos D.","year":"2006","unstructured":"Antos D.; Schneider-Brachert W.; Bastlein E.; 7-Day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimi- crobial sensitivity. Helicobacter 2006,11,39-45","journal-title":"Helicobacter"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/1751-2980.12024","volume":"14","author":"Ang T.L.","year":"2013","unstructured":"Ang T.L.; Wang L.; Ang D.; Chiam P.; Fock K.M.; Teo E.K.; Is there still a role for empiric first-line triple therapy using proton pump inhibi-tor, amoxicillin and clarithromycin for Helicobacter pylori infection in Singapore? Results of a time trend analysis. J Dig Dis 2013,14(2),100-104","journal-title":"J Dig Dis"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00535-008-2187-4","volume":"43","author":"Usta Y.","year":"2008","unstructured":"Usta Y.; Saltik-Temizel I.N.; Demir H.; Comparison of short- and long-term treatment protocols and the results of second-line quad-ruple therapy in children with Helicobacter pylori infection. J Gastroenterol 2008,43(6),429-433","journal-title":"J Gastroenterol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1523-5378.2007.00548.x","volume":"12","author":"Kang J.M.","year":"2007","unstructured":"Kang J.M.; Kim N.; Lee D.H.; Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter 2007,12,623-628","journal-title":"Helicobacter"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.3748\/wjg.v18.i32.4386","volume":"18","author":"Francesco Ciccaglione A.","year":"2012","unstructured":"Francesco Ciccaglione A.; Cellini L.; Grossi L.; Marzio L.; Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori. World J Gastroenterol 2012,18(32),4386-4390","journal-title":"World J Gastroenterol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1046\/j.1365-2036.2000.00776.x","volume":"14","author":"Katelaris P.H.","year":"2000","unstructured":"Katelaris P.H.; Adamthwalte D.; Midoloa P.; Yeomans N.D.; Randomized trial of omeprazole and metronidazole with amoxicillin or clar-ithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. Aliment Pharmacol Ther 2000,14,751-758","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1046\/j.1365-2036.2001.01104.x","volume":"15","author":"Laurent J.","year":"2001","unstructured":"Laurent J.; Graud F.M.; FleaJoua JF, Caekaert A, BartheaLemy P. A randomized comparison of four omeprazole-based triple ther- apy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2001,15,1787-1793","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1056\/NEJM199812243392601","volume":"339","author":"Mccolin K.","year":"2002","unstructured":"Mccolin K.; Murray L.; El-Omar E.; Symptomatic benefit from eradicating Helicobacter pylori infectioninpatient. N Engl J Med 2002,339(26),1869-1874","journal-title":"N Engl J Med"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1046\/j.1365-2036.2003.01659.x","volume":"18","author":"Isomoto H.","year":"2003","unstructured":"Isomoto H.; Inoue K.; Furusu H.; High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2003,18(1),101-107","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1523-5378.2009.00664.x","volume":"14","author":"Ueki N.","year":"2009","unstructured":"Ueki N.; Miyake K.; Kusunoki M.; Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure. Helicobacter 2009,14(2),91-99","journal-title":"Helicobacter"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/ajg.2008.87","volume":"104","author":"Rokkas T.","year":"2009","unstructured":"Rokkas T.; Sechopoulos P.; Robotis L.; Margantinis G.; Pistiolas D.; Cumulative H. pylori eradication rates in clinical practice by adopting first and second-Line regimens proposed by the maas- tricht III consensus and a third-Line empirical regimen. Am J Gastroenterol 2009,104,21-25","journal-title":"Am J Gastroenterol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/ajg.2009.508","volume":"105","author":"Luther J.","year":"2010","unstructured":"Luther J.; Higgins P.D.R.; Schoenfeld P.S.; Moayyedi P.; Vakil N.; Chey W.D.; Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010,105(1),65-73","journal-title":"Am J Gastroenterol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1590\/1414-431X20132817","volume":"46","author":"Zhang G.","year":"2013","unstructured":"Zhang G.; Zou J.; Liu F.; The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: A systemat-ic review and meta-analysis of randomized clinical trials. Braz J Med Biol Res 2013,46(7),607-613","journal-title":"Braz J Med Biol Res"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1523-5378.2009.00671.x","volume":"14","author":"Essa A.S.","year":"2009","unstructured":"Essa A.S.; Kramer J.R.; Graham D.Y.; Treiber G.; Meta-analysis: Four-drug, three-antibiotic, non-bismuth-containing \u201cconcomitant therapy\u201d versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009,14(2),109-118","journal-title":"Helicobacter"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1046\/j.1365-2036.2000.00744.x","volume":"14","author":"Calvet X.","year":"2000","unstructured":"Calvet X.; Garc\u00eda N.; L\u00f3pez T.; Gisbert J.P.; Gen\u00e9 E.; Roque M.; A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000,14(5),603-609","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"553","DOI":"10.7326\/0003-4819-147-8-200710160-00008","volume":"147","author":"Fuccio L.","year":"2007","unstructured":"Fuccio L.; Minardi M.E.; Zagari R.M.; Grilli D.; Magrini N.; Bazzoli F.; Meta-analysis: Duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007,147(8),553-562","journal-title":"Ann Intern Med"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"Jadad A.R.","year":"1996","unstructured":"Jadad A.R.; Moore R.A.; Carroll D.; Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996,17(1),1-12","journal-title":"Control Clin Trials"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/gut.2006.102269","volume":"56","author":"Zagari R.M.","year":"2007","unstructured":"Zagari R.M.; Bianchi-Porro G.; Fiocca R.; Gasbarrini G.; Roda E.; Bazzoli F.; Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: The Hyper study. Gut 2007,56(4),475-479","journal-title":"Gut"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrgastro.2010.210","volume":"8","author":"Rimbara E.","year":"2011","unstructured":"Rimbara E.; Fischbach L.A.; Graham D.Y.; Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011,8(2),79-88","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/j.1440-1746.2009.05982.x","volume":"24","author":"Fock K.M.","year":"2009","unstructured":"Fock K.M.; Katelaris P.; Sugano K.; Second Asia-pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009,24(10),1587-1600","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1523-5378.2009.00738.x","volume":"15","author":"Asaka M.","year":"2010","unstructured":"Asaka M.; Kato M.; Takahashi S.; Guidelines for the management of Helicobacter pylori infection in Japan. Helicobacter 2010,15(1),1-20","journal-title":"Helicobacter"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1523-5378.2008.00631.x","volume":"13","author":"Bruce M.G.","year":"2008","unstructured":"Bruce M.G.; Maaroos H.I.; Epidemiology of Helicobacter pylori infection. Helicobacter 2008,13(1),1-6","journal-title":"Helicobacter"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1523-5378.2011.00874.x","volume":"16","author":"Goh K.L.","year":"2011","unstructured":"Goh K.L.; Chan W.K.; Shiota S.; Yamaoka Y.; Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2011,16(1),1-9","journal-title":"Helicobacter"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1523-5378.2011.00842.x","volume":"16","author":"Hori K.","year":"2011","unstructured":"Hori K.; Miwa H.; Matsumoto T.; Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population. Helicobacter 2011,16(3),234-240","journal-title":"Helicobacter"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1586\/eri.09.113","volume":"8","author":"Boyanova L.","year":"2010","unstructured":"Boyanova L.; Mitov I.; Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther 2010,8(1),59-70","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/j.1572-0241.2006.00717.x","volume":"101","author":"Padol S.","year":"2006","unstructured":"Padol S.; Yuan Y.; Thabane M.; Padol I.T.; Hunt R.H.; The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: A meta-analysis. Am J Gastroenterol 2006,101(7),1467-1475","journal-title":"Am J Gastroenterol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/j.1365-2036.2007.03386.x","volume":"26","author":"Fischbach L.","year":"2007","unstructured":"Fischbach L.; Evans E.L.; Meta-analysis: The effect of antibiotic resistance status on the efficacy of triple and quadruple first-line thera-pies for Helicobacter pylori. Aliment Pharmacol Ther 2007,26(3),343-357","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/j.1365-2036.2004.02248.x","volume":"20","author":"Fischbach L.A.","year":"2004","unstructured":"Fischbach L.A.; van Zanten S.V.; Dickason J.; Meta-analysis: The efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004,20(10),1071-1082","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1523-5378.2007.00518.x","volume":"12","author":"Graham D.Y.","year":"2007","unstructured":"Graham D.Y.; Lu H.; Yamaoka Y.; A report card to grade Helicobacter pylori therapy. Helicobacter 2007,12(4),275-278","journal-title":"Helicobacter"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.2169\/internalmedicine.48.2344","volume":"48","author":"Wenzhen Y.","year":"2009","unstructured":"Wenzhen Y.; Kehu Y.; Bin M.; Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: A meta-analysis of randomized controlled trials. Intern Med 2009,48(24),2069-2076","journal-title":"Intern Med"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2165\/00003495-200868060-00001","volume":"68","author":"Graham D.Y.","year":"2008","unstructured":"Graham D.Y.; Lu H.; Yamaoka Y.; Therapy for Helicobacter pylori infection can be improved: Sequential therapy and beyond. Drugs 2008,68(6),725-736","journal-title":"Drugs"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/ncpgasthep1138","volume":"5","author":"Graham D.Y.","year":"2008","unstructured":"Graham D.Y.; Shiotani A.; New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008,5(6),321-331","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1586\/17474124.2.4.577","volume":"2","author":"Snaith A.","year":"2008","unstructured":"Snaith A.; El-Omar E.M.; Helicobacter pylori: Host genetics and disease outcomes. Expert Rev Gastroenterol Hepatol 2008,2(4),577-585","journal-title":"Expert Rev Gastroenterol Hepatol"}],"container-title":["Current Reviews in Clinical and Experimental Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2772432818666230120111237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/212941\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2772432818666230120111237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T07:41:36Z","timestamp":1701243696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/212941\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":118,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2772432818666230120111237","relation":{},"ISSN":["2772-4328"],"issn-type":[{"value":"2772-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}